3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
66
Rituximab
43
fludarabine phosphate
37
Methotrexate
36
Whole-Body Irradiation
34
Peripheral Blood Stem Cell Transplantation
34
Vincristine
33
Etoposide
32
Cytarabine
29
Mycophenolic Acid
28
Tacrolimus
23
Busulfan
23
Prednisone
22
Doxorubicin
22
Filgrastim
21
merphos
20
Dexamethasone
20
Cyclosporine
19
Melphalan
18
Calcium Dobesilate
18
Granulocyte Colony-Stimulating Factor
17
Antilymphocyte Serum
17
Radiotherapy
16
Leucovorin
15
dexamethasone acetate
14
dexamethasone 21-phosphate
14
auricularum
13
prednylidene
12
deltacortene
12
azathiopurine
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Burkitt Lymphoma
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts